DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Stintzing S. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Ann Oncol 2012;
23: 1693-1699
We do not assume any responsibility for the contents of the web pages of other providers.